- Trial registry record
- Trial registry update
The n-Lorem Foundation, a nonprofit, made nL-GARS1-001, an antisense drug designed for one participant whose CMT2D is caused by a GARS1 deletion. The study runs at UTHealth Houston and enrols by invitation only.
No results have been posted. The registry expects the study to finish in October 2027.
- Source date
- Source updated
- Registry status
- Enrolling by invitation
- Results posted to ClinicalTrials.gov
- No
- Genes
- GARS1
- Subtypes
- CMT2D
- Approved